GSK posts blowout RSV vaccine sales, raises outlook as shots

The RSV shot, called Arexvy, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year. 

Related Keywords

Japan , United Kingdom , Canada , British , Albert Bourla , Emma Walmsley , Pfizer , Drug Administration , Chief Executive Officer Emma Walmsley , News ,